Samsung生物logics保证了价值超过6.68亿美元的重大交易,标志着大幅度增长和利润。 Samsung Biologics secures major deals worth over $668 million, marking significant growth and profitability.

南韩制药公司三星生化公司(Samsung Biologics)与一家价值超过6.68亿美元的欧洲公司签署了新制造交易, Samsung Biologics, a South Korean pharmaceutical company, has signed new manufacturing deals with a European firm worth over $668 million, pushing its annual deal value past 5 trillion won for the first time. 该公司最近还与一家亚洲公司达成12.4亿美元的交易。 The company also recently secured a $1.24 billion deal with an Asian firm. Samsung生物生物学今年有了显著增长,净利润增加了72%,营业利润增加了47%。 Samsung Biologics has seen significant growth this year, with a 72% increase in net profit and a 47% rise in operating profit. 该公司现在服务于世界前20家制药公司中的17家,并计划在年终之前增加ADC服务。 The company now serves 17 of the world's top 20 pharmaceutical firms and plans to add ADC services by year-end.